logo
Plus   Neg
Share
Email

Lilly Announces Interim Analysis From EMPRISE Real-world Study

Eli Lilly and Co. (LLY) said that a new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty or EMPRISE real-world study on effectiveness shows that Jardiance or empagliflozin was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists.

The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease.

In this new interim analysis, Jardiance was associated with a reduction in risk of hospitalization for heart failure of 41% compared with DPP-4 inhibitors and of 17% compared with GLP-1 receptor agonists.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Video streaming giant Netflix announced plans to significantly increase its investment in France with 20 new French productions, and partnerships with leading French creative institutions. Netflix on Monday opened its new headquarters in France, located in the heart of Paris. Netflix France currently... Toyota Motor Corp. has invested $394 million in U.S. electric air-taxi startup Joby Aviation as lead investor in the recent $590 million Series C financing. Toyota said it is continuing to leverage emerging technologies to provide "Mobility for All" as the lead investor as part of its transformation into a mobility company. As the world is facing severe consequences of increasing carbon emissions, Microsoft has announced various plans to tackle the issue. The company aims to reduce its own carbon emissions by more than half, and to be carbon negative by 2030. This means the company will remove more carbon than it emits each year. The company further announced a new $1 billion Climate Innovation Fund.
Follow RTT
>